Related Experiment Video

Updated: Sep 21, 2026

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

Soluble oligomers for the diagnosis of neurodegenerative diseases

Omar M A El-Agnaf1, Dominic M Walsh, David Allsop

  • 1Department of Biological Sciences, Lancaster University, Lancaster, UK. o.el-agnaf@lancaster.ac.uk

The Lancet. Neurology
|July 25, 2003
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Related Experiment Videos

Last Updated: Sep 21, 2026

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...

Articles linked to this work by shared authors, journal, and citation graph.

Intra-CNS AAV9-GBA1 delivery yields species and route of administration differences in safety and transgene expression.

Molecular therapy. Advances·2026

Immunotherapy with B28, an antibody to Aβ oligomers, potently decreases amyloid plaques, microgliosis, and memory decline in APP knock-in mice.

Cell reports·2026

Distinct Molecular Mechanisms Underlie Modulation of Seeded α-Synuclein Aggregation and Toxicity by Salvianolic Acid B and Dihydromyricetin.

International journal of molecular sciences·2026

Post-booster longitudinal plasma proteomic changes following BNT162b2 COVID-19 vaccination in Qatar.

Frontiers in immunology·2026

Novel Monoclonal Antibody Detects Small Aβ Oligomers More Sensitively Than Lecanemab in Alzheimer's Disease CSF, Serum and Culture Media.

Annals of neurology·2026

Identification of aryl hydrocarbon receptor as a functional target that enhances astrocytic ApoE secretion.

Cell chemical biology·2026

Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study.

The Lancet. Neurology·2026

Plasma phosphorylated tau 217 concentrations, APOE genotype, and timing of cognitive impairment in individuals across diverse racial and ethnic groups: a pooled analysis of prospective cohort studies.

The Lancet. Neurology·2026

Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change.

The Lancet. Neurology·2026

Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy.

The Lancet. Neurology·2026

Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders.

The Lancet. Neurology·2026

Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

The Lancet. Neurology·2026

Sleep Bursts of Cranial Forces- a Potential Marker of Neurodegenerative Disease.

bioRxiv : the preprint server for biology·2026

Unraveling the roles of anemia, renal impairment, and neuroinflammation in hemodialysis-associated cognitive dysfunction in chronic kidney disease patients.

The International journal of artificial organs·2026

Neural Correlates of Apathy in Multiple System Atrophy: A Clinical and Perfusion Imaging Study.

European journal of neurology·2026

Critical Kennedy's disease with Guillain-Barré syndrome and respiratory failure: A case report.

Medicine·2026

A previously unreported ELOVL4 frameshift variant in a patient with early severe cognitive decline, parkinsonism, and cerebellar ataxia: A case report.

Medicine·2026

Efficacy of Curcumin in Neurodegenerative Diseases: From Pharmacokinetic Barriers to Advanced Delivery Systems.

Pharmaceuticals (Basel, Switzerland)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us